Celldex Therapeutics reported $13.1M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Agenus USD 6.21M 4.34M Mar/2026
Amgen USD 1.72B 134M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Celldex Therapeutics USD 13.1M 1.65M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Northwest Biotherapeutics USD 6.54M 534K Mar/2026
Pfizer USD 3.41B 496M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 6.37B 908M Jun/2026